Edition:
United States

Merck KGaA (MRCG.DE)

MRCG.DE on Xetra

111.15EUR
23 Jun 2017
Change (% chg)

€-0.55 (-0.49%)
Prev Close
€111.70
Open
€111.55
Day's High
€112.65
Day's Low
€110.65
Volume
622,217
Avg. Vol
406,308
52-wk High
€115.20
52-wk Low
€82.00

MRCG.DE

Chart for MRCG.DE

About

Merck KGaA is a Germany-based company engaged in the pharmaceutical industry. The Company operates through four business segments: Merck Serono; Consumer Health; Merck Millipore, and Performance Materials. Within the Merck Serono division, the Company focuses on therapeutic areas and prescription drugs of chemical and biotechnol... (more)

Overall

Beta: 1.01
Market Cap(Mil.): €14,365.28
Shares Outstanding(Mil.): 129.24
Dividend: 1.20
Yield (%): 1.08

Financials

  MRCG.DE Industry Sector
P/E (TTM): 30.98 14.09 19.01
EPS (TTM): 3.59 -- --
ROI: 5.48 -6.73 -5.03
ROE: 11.76 -6.18 -4.28

Germany's Merck gets EU backing for oral MS drug

(This June 23 story corrects second paragraph to show that the recommendation is to approve the relapsing forms, not the relapsing-remitting form of MS.)

Jun 24 2017

CORRECTED-Germany's Merck gets EU backing for oral MS drug

FRANKFURT, June 23 Germany's Merck KGaA has won a key recommendation to become a late entrant to the market for oral multiple sclerosis (MS) drugs in Europe, six years after its first attempt to launch the cladribine pill failed.

Jun 24 2017

BRIEF-EMA recommends approval of Merck's multiple sclerosis drug

* EU Medicines Agency recommends approval of Merck KGAA multiple sclerosis drug

Jun 23 2017

BRIEF-Effector Therapeutics to collaborate with Pfizer and Merck to evaluate immuno-oncology combination in microsatellite stable colorectal cancer

* Effector Therapeutics to collaborate with Pfizer and Merck KGAA to evaluate a novel immuno-oncology combination in microsatellite stable colorectal cancer

Jun 20 2017

BRIEF-Merck awarded first CRISPR patent by Australian patent office

* Awarded first CRISPR patent by Australian patent office Further company coverage:

Jun 14 2017

CORRECTED-Merck KGaA: 2 bln eur pipeline potential driven by cancer, MS drugs

FRANKFURT, June 12 Germany's Merck KGaA said its forecast of 2 billion euros ($2.24 billion) in 2022 sales from drugs under development was above the analyst consensus mainly because of the underrated potential of cancer drug avelumab and multiple sclerosis treatment cladribine.

Jun 13 2017

BRIEF-Merck KGaA enters immuno-oncology collaboration with F-Star

* Strengthens immuno-oncology portfolio through expansion of F-star collaboration including LAG-3/PD-L1 bispecific antibody- new strategic collaboration to develop and commercialize bispecific immuno-oncology antibodies

Jun 04 2017

Merck KGaA TV crystals sales decline raises stakes for cancer drug

FRANKFURT Merck KGaA's sales of liquid crystals used in flat-screen TVs are now expected to decline this year, making the German company more reliant on its new cancer immunotherapy drug to fuel growth.

May 18 2017

UPDATE 1-Merck KGaA TV crystals sales decline raises stakes for cancer drug

* Sees 2017 adjusted earnings of 4.4 bln-4.6 bln euros (Adds analyst, CFO quotes, details on crystals, cancer drug)

May 18 2017

BRIEF-Merck KGaA says losing some market share in liquid crystals to new Chinese rivals

* CFO says seeing no signs of weakening demand at life science division

May 18 2017

More From Around the Web

Earnings vs. Estimates